Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Epilepsy Clear all
Completed Phase 2Phase 3 Interventional Results available

Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.

NCT02710890
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loxahatchee Groves, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Not listed No phase listed Observational

Clinical Validation of zEEG, a Wireless EEG Recording System for Pediatric and Adult Patients With Epilepsy

NCT05123469
View directory record Official record
Conditions
Epilepsy, EEG With Periodic Abnormalities, EEG With Abnormally Slow Frequencies, EEG; Paroxysms, Occipital, Epilepsy of Childhood, EEG; Spikes, Centrotemporal, Epilepsy of Childhood
Interventions
Electroencephalography
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
1 Year to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

NCT02318602
View directory record Official record
Conditions
Seizures
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
1 Year to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

Pediatric Epilepsy Study

NCT00050947
View directory record Official record
Conditions
Epilepsy
Interventions
oxcarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 16 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Madera, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Sep 25, 2026, 4:13 AM EDT
Completed No phase listed Observational

Pediatric Seizure Movement Bed Alarm

NCT01855178
View directory record Official record
Conditions
Seizures, Sleep, Epilepsy
Interventions
Emfit Movement Monitor
Device
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
Up to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Sep 25, 2026, 4:13 AM EDT
Withdrawn Not applicable Interventional

Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery

NCT04344626
View directory record Official record
Conditions
Epilepsy, Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly, Polymicrogyria, Rasmussen Encephalitis, Sturge-Weber Syndrome, Gliosis, Stroke, Tumor, Brain
Interventions
Intra-operative brain tonometry
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

NCT07600736
View directory record Official record
Conditions
KCNT1-Related Epilepsy
Interventions
ABS-1230, Placebo
Drug
Lead sponsor
Actio Biosciences, Inc.
Industry
Eligibility
1 Month to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Retraining and Control Therapy (ReACT) R33 Phase

NCT06007053
View directory record Official record
Conditions
Convulsion, Non-Epileptic
Interventions
ReACT, Supportive Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years to 18 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

NCT07227857
View directory record Official record
Conditions
Epileptic Encephalopathy
Interventions
S230815- Starting dose A, S230815- Dose B, S230815- Dose C, S230815- Dose D
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
2 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Orange, California • Boston, Massachusetts • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Withdrawn Not applicable Interventional

Effect of Music Therapy on Cognitive Recovery

NCT01947088
View directory record Official record
Conditions
Epilepsy
Interventions
Music Therapy
Behavioral
Lead sponsor
Seton Healthcare Family
Other
Eligibility
6 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 25, 2026, 4:13 AM EDT
Recruiting Phase 3 Interventional

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

NCT04462770
View directory record Official record
Conditions
Dravet Syndrome
Interventions
Clemizole HCl, Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

NCT03336242
View directory record Official record
Conditions
Childhood Absence Epilepsy
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

NCT01364597
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam (BRV)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
28 Days to 17 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Gulf Breeze, Florida • Wellington, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

NCT02324673
View directory record Official record
Conditions
Seizures
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
1 Year to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Pensacola, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

Clinical Utility of Pediatric Whole Exome Sequencing

NCT03525431
View directory record Official record
Conditions
Encephalopathy, Birth Defect, Intellectual Disability, Multiple Congenital Anomaly, Metabolic Disease, Epilepsy, Neuro-Degenerative Disease, Cerebral Palsy, Developmental Delay, Developmental Defect
Interventions
Whole Exome Sequencing
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 25 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Fresno, California • Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

NCT04938427
View directory record Official record
Conditions
Lennox Gastaut Syndrome (LGS)
Interventions
Placebo, Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies

NCT02358538
View directory record Official record
Conditions
Epilepsy
Interventions
Ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

NCT01284530
View directory record Official record
Conditions
Epilepsy
Interventions
TPM XR
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Sacramento, California • Loxahatchee Groves, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

Pediatric Epilepsy Study

NCT00050934
View directory record Official record
Conditions
Epilepsy, Epilepsies, Partial
Interventions
oxcarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 3 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 4 Interventional

Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population

NCT00207935
View directory record Official record
Conditions
Epilepsy, Mental Retardation, Developmental Disabilities
Interventions
Swallow instruction
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
4 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 4, 2008 · Synced Sep 25, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915
View directory record Official record
Conditions
Generalized Tonic Clonic Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 25, 2026, 4:13 AM EDT
Not listed Phase 1Phase 2 Interventional

Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy

NCT04219995
View directory record Official record
Conditions
Intractable Epilepsy, Convulsive Seizures
Interventions
methylprednisolone sodium succinate, Placebo
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
2 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 25, 2026, 4:13 AM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Xcopri
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Palo Alto, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 4:13 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 25, 2026, 4:13 AM EDT